Journal of Cancer Research and Clinical Oncology

, Volume 137, Issue 7, pp 1105–1115

Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach

Authors

    • Department of General Surgery, Graduate School of MedicineChiba University
    • Department of Molecular Diagnosis, Graduate School of MedicineChiba University
  • Takafumi Sangai
    • Department of General Surgery, Graduate School of MedicineChiba University
  • Takeshi Nagashima
    • Department of General Surgery, Graduate School of MedicineChiba University
  • Masahiro Sakakibara
    • Department of General Surgery, Graduate School of MedicineChiba University
  • Hideyuki Yoshitomi
    • Department of General Surgery, Graduate School of MedicineChiba University
  • Shigetsugu Takano
    • Department of General Surgery, Graduate School of MedicineChiba University
  • Kazuyuki Sogawa
    • Department of Molecular Diagnosis, Graduate School of MedicineChiba University
  • Hiroshi Umemura
    • Department of Molecular Diagnosis, Graduate School of MedicineChiba University
  • Koya Fushimi
    • Department of General Surgery, Graduate School of MedicineChiba University
  • Yukio Nakatani
    • Department of Diagnostic Pathology, Graduate School of Medicine, Chiba University, and Department of PathologyChiba University Hospital
  • Fumio Nomura
    • Department of Molecular Diagnosis, Graduate School of MedicineChiba University
  • Masaru Miyazaki
    • Department of General Surgery, Graduate School of MedicineChiba University
Original Paper

DOI: 10.1007/s00432-010-0974-9

Cite this article as:
Kadowaki, M., Sangai, T., Nagashima, T. et al. J Cancer Res Clin Oncol (2011) 137: 1105. doi:10.1007/s00432-010-0974-9

Abstract

Purpose

Breast cancer is the most frequent malignancy in women. However, no useful serum markers with high sensitivity and specificity for the detection of early breast cancer have been identified. The search for biological markers of early breast cancer is of continual interest in experimental and clinical breast cancer research. We recently described a simple and highly reproducible three-step proteome analysis for identifying potential disease-marker candidates among the low-abundance serum proteins.

Methods

Serum samples from breast ductal carcinoma in situ (DCIS) patients and normal controls were subjected to a three-step serum proteome analysis. The steps were the following: first, immunodepletion of most abundant proteins; second, fractionation using reverse-phase high-performance liquid chromatography; and third, separation using two-dimensional electrophoresis (2-DE). Differences revealed by protein staining were further confirmed by Western blotting, immunohistochemical staining, and enzyme-linked immunosorbent assays (ELISA).

Results

Twenty-two upregulated and 26 downregulated spots were detected on the 2-DE gels, and a total of 33 proteins were identified by liquid chromatography and tandem mass spectrometry. Western blotting confirmed that the level of vitronectin was significantly increased in DCIS patients compared with that of normal controls. Immunohistochemical staining of vitronectin in breast cancer tissue revealed high expression in small vessel walls surrounding cancer cells and the extracellular matrix of stroma. Moreover, vitronectin serum concentrations, as measured by ELISA, were significantly increased in patients with DCIS or more advanced breast cancer compared with those of normal controls.

Conclusions

Vitronectin could serve as a promising serum marker for the detection of primary breast cancer.

Keywords

Breast cancer Proteomics Serum marker Immunodepletion Vitronectin

Abbreviations

LC–MS/MS

Liquid chromatography and tandem mass spectrometry

DCIS

Ductal carcinoma in situ

ELISA

Enzyme-linked immunosorbent assay

HPLC

High-performance liquid chromatography

SDS–PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

IEF

Isoelectric focusing

2-DE

Two-dimensional electrophoresis

ROC

Receiver-operating characteristics

AU

Arbitrary units

AUC

Area under the ROC curve

ER

Estrogen receptor

PgR

Progesterone receptor

PAI-1

Plasminogen activator inhibitor-1

uPAR

Urokinase plasminogen activator receptor

Copyright information

© Springer-Verlag 2011